Why do some patients thrive on GLP-1 therapy while others do not? An ayurvedic perspective on metabolic heterogeneity
EXPLORE · 2026-11 · 22 (6) · 103540
DOI: 10.1016/j.explore.2026.103540 ↗Kurz gefasst
Fachartikel in der Zeitschrift EXPLORE, 2026-11. Verfasst von Uma Purighalla. Beteiligte Einrichtung: Center for Community Hospital Medicine, UPMC Passavant Hospital, Pittsburgh, PA, USA; ServeFed - Federal Occupational Health, USA; Purighalla Wellnes…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Community Hospital Medicine, UPMC Passavant Hospital, Pittsburgh, PA, USA; ServeFed - Federal Occupational Health, USA; Purighalla Wellness LLC, Allison Park, PA, USA. Electronic address: umapurighalla@outloo…
Zitieren
APA
Purighalla, U. (2026). Why do some patients thrive on GLP-1 therapy while others do not? An ayurvedic perspective on metabolic heterogeneity. EXPLORE, 22(6), 103540. https://doi.org/10.1016/j.explore.2026.103540
Vancouver
Purighalla U. Why do some patients thrive on GLP-1 therapy while others do not? An ayurvedic perspective on metabolic heterogeneity. EXPLORE. 2026;22(6):103540. doi:10.1016/j.explore.2026.103540
BibTeX
@article{Purighalla2026,
author = {Purighalla, Uma},
title = {Why do some patients thrive on GLP-1 therapy while others do not? An ayurvedic perspective on metabolic heterogeneity},
journal = {EXPLORE},
year = {2026},
volume = {22},
number = {6},
pages = {103540},
doi = {10.1016/j.explore.2026.103540}
}
EUVIMED